AcariaHealth Sparks Innovation at 2025 Healthcare Advocate Summit with Hackathon and Expert Panels

26.08.25 14:40 Uhr

Werte in diesem Artikel
Aktien

32,99 EUR 0,20 EUR 0,61%

LAS VEGAS, Aug. 26, 2025 /PRNewswire/ -- AcariaHealth, a leader in specialty pharmacy solutions and a Centene Corporation company (NYSE: CNC), is taking center stage at the 2025 Healthcare Advocate Summit (Sept. 2–5) in Las Vegas with a first-of-its-kind "Reimagine Access" Hackathon and two can't-miss expert sessions.

AcariaHealth is a national specialty pharmacy dedicated to supporting patients with complex conditions through personalized care and clinical expertise. As a Centene company, AcariaHealth leverages the strength of the largest Medicaid managed care organization to deliver transformative outcomes across the country. (PRNewsfoto/AcariaHealth)

Reimagine Access: A Hackathon for Healthcare Advocates
Tuesday, Sept. 2 | 1:00–3:30 PM PT | Florentine 1–11

This dynamic, hands-on session brings together healthcare advocates, providers, and pharmacy professionals for fast-paced, themed breakout discussions focused on real-world access challenges:

  • Breaking Bio – Biosimilars & Continuity of Care
  • No Place Like Home – Reimagining Home Infusion
  • Coverage Unlocked – Medicare/Medicaid Access
  • The Access Avengers – SP + Advocate Partnerships
  • Pharmaformers – Transforming Specialty Pharmacy

Guided by AcariaHealth Regional Sales Directors, each table invites participants to brainstorm actionable solutions they can take back to their organizations.

Expert Panel: Biosimilars & Market Disruption
Thursday, Sept. 4 | 1:30–2:20 PM PT

Join AcariaHealth leaders as they break down biosimilar trends, payer mandates, and how to prevent care disruption. Featuring a new video spotlighting our Provider Experience Managers (PEMs) and their impact on provider-pharmacy collaboration.

Panelists:

  • Alysha Robinson, PharmD, CSP – Director, Specialty Pharmacy Program Management
  • Kathleen Stenberg, PharmD, CSP – Lead Specialty Pharmacist, Operational Excellence
  • Robin Waida – Director, Physician Sales
  • Gil Rosas, BSN – Account Executive

Can't attend? Register for our October Biosimilars Webinar.

Roundtable: M3P Unpacked – Your Final Questions, Clarified
Friday, Sept. 5 | 8:30–9:30 AM PT | Pompeian 1–11
Speaker: Sheri Wallace - Account Executive

Wrap up the Summit with this interactive discussion on the Medicare Prescription Payment Plan (M3P) and its implications for patients and advocates. No slides—just your questions answered.

Advancing Access, Together
"At AcariaHealth, we believe access to care should be as seamless as the care itself," said Jessica Ciccolella-Kahl, CEO of AcariaHealth. "We're proud to lead these conversations and help drive lasting solutions."

From biosimilar transitions to breakthrough collaborations, AcariaHealth is committed to reshaping specialty pharmacy through innovation, advocacy, and compassion.

Heading to the Healthcare Advocate Summit? Stop by our sessions, meet the team, and follow us on LinkedIn for live updates.

About AcariaHealth
AcariaHealth is a national specialty pharmacy dedicated to supporting patients with complex conditions through personalized care and clinical expertise. As a Centene company, AcariaHealth leverages the strength of the largest Medicaid managed care organization to deliver transformative outcomes across the country.
Learn more: AcariaHealth.com
Follow us on LinkedIn

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/acariahealth-sparks-innovation-at-2025-healthcare-advocate-summit-with-hackathon-and-expert-panels-302538826.html

SOURCE AcariaHealth

In eigener Sache

Übrigens: Centene und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Centene

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Centene

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Centene Corp.

Wer­bung

Analysen zu Centene Corp.

DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
15.06.2015Centene HoldDeutsche Bank AG
15.06.2015Centene Mkt PerformFBR Capital
28.04.2015Centene Mkt PerformFBR Capital
11.02.2015Centene NeutralUBS AG
15.12.2014Centene HoldDeutsche Bank AG
DatumRatingAnalyst
05.12.2006Update Centene Corp.: SellGoldman Sachs
12.06.2006Update Centene Corp.: SellMatrix Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Centene Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen